Back to top
more

SARTORIUS (SARTF)

(Delayed Data from OTC)

$235.81 USD

235.81
2

0.00 (0.00%)

Updated Apr 23, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

SARTORIUS (SARTF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

SARTORIUS (SARTF) Q3 Earnings Lag Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of -23.65% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.39% and 7.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynatronics Corporation (DYNT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -11.11% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 6.56% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 10.04% and 8.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 1.24% and 1.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Looking for a Growth Stock? 3 Reasons Why SARTORIUS (SARTF) is a Solid Choice

by Zacks Equity Research

SARTORIUS (SARTF) possesses solid growth attributes, which could help it handily outperform the market.

Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up

by Zacks Equity Research

Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

by Zacks Equity Research

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View

by Zacks Equity Research

Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.

Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up

by Zacks Equity Research

Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.

IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls

by Zacks Equity Research

IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.

Bruker (BRKR) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Bruker (BRKR) reports better-than-expected earnings and revenues for the third quarter of 2021 on geographical performance driving the top line.

Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up

by Zacks Equity Research

Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.

3 Reasons Why SARTORIUS (SARTF) Is a Great Growth Stock

by Zacks Equity Research

SARTORIUS (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SARTORIUS (SARTF) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.59% and 5.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

SARTORIUS (SARTF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SARTORIUS AG (SARTF) Surges 3.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

SARTORIUS AG (SARTF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here is Why Growth Investors Should Buy SARTORIUS AG (SARTF) Now

by Zacks Equity Research

SARTORIUS AG (SARTF) is well positioned to outperform the market, as it exhibits above-average growth in financials.